Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206085 | 0.88 | ADRB2 (0.43) | LMNAALDH1A1 | |
| SCHEMBL26206322 | 0.84 | MAPT (0.43) | S1PR2S1PR1S1PR3HSD17B10 | |
| SCHEMBL26206414 | 0.82 | LMNA (0.54) | FFAR1LMNAL3MBTL1 | |
| SCHEMBL26206355 | 0.79 | ALDH1A1 (0.44) | FFAR1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL26206356 | 0.79 | ALDH1A1 (0.44) | FFAR1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL26206360 | 0.79 | ALDH1A1 (0.44) | FFAR1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL22526938 | 0.78 | ATM (0.40) | FFAR1CA2 | |
| SCHEMBL26206459 | 0.78 | FFAR1 (0.47) | FFAR1LMNAL3MBTL1S1PR2S1PR1 | |
| SCHEMBL26206388 | 0.77 | MAPT (0.50) | FFAR1S1PR2S1PR1S1PR3HSD17B10 | |
| SCHEMBL26206075 | 0.74 | ADRB2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | FFAR1 4114/4885LMNA 4438/4885L3MBTL1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.